Wafra Inc. Eli Lilly & CO Transaction History

Wafra Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$592.2 - $792.28 $1.02 Million - $1.37 Million	-1,728 Reduced 2.62%	64,313 $50 Million
Q4 2023 Feb 08, 2024	SELL	$525.19 - $619.13 $34.8 Million - $41 Million	-66,183 Reduced 50.05%	66,041 $38.5 Million
Q2 2023 Jul 21, 2023	BUY	$350.74 - $468.98 $19.9 Million - $26.6 Million	56,784 Added 75.27%	132,224 $62 Million
Q1 2023 May 04, 2023	BUY	$310.63 - $364.82 $23.4 Million - $27.5 Million	75,440 New	75,440 $25.9 Million

4,011

751M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $756B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Wafra Inc., based on Form 13F filings with the SEC.

Stay updated on Wafra Inc. with notifications on news.